Saligenin analogs of l-DOPA and dl-alpha-methyl-DOPA.
D000818:Animals; D000978:Antiparkinson Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003900:Desoxycorticosterone / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000494:pharmacology*; D004296:Dopa Decarboxylase / Q000378:metabolism; D006168:Guinea Pigs; D006220:Haloperidol / Q000037:antagonists & inhibitors; D007668:Kidney / Q000201:enzymology; D000432:Methanol / Q000138:chemical synthesis / Q000494:pharmacology; D008750:Methyldopa / Q000494:pharmacology*; D008781:Methyltyrosines / Q000138:chemical synthesis* / Q000494:pharmacology; D051379:Mice; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D014443:Tyrosine / Q000138:chemical synthesis* / Q000494:pharmacology
D000978:Antiparkinson Agents; D008781:Methyltyrosines; D003900:Desoxycorticosterone; D014443:Tyrosine; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D004296:Dopa Decarboxylase; D006220:Haloperidol; D009638:Norepinephrine; D000432:Methanol